Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express

08/06

Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.

The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.

Pharmaron’s current board composition comprises: • Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei • Employee Representative Director: Mr. Li Shing Chung Gilbert • Non-executive Director: Ms. Wan Xuan • Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong

No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1182061725"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182061725\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182061725?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182061725","market":"us","top_or_hot":-1,"title":"Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.</p>\n<p>The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.</p>\n<p>Pharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong</p>\n<p>No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-06 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.</p>\n<p>The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.</p>\n<p>Pharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong</p>\n<p>No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1182061725","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182061725","pubTimestamp":1786005958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成将于 2026 年 8 月 20 日召开董事会会议，批准 2026 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.\nThe announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.\nPharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong\nNo additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}